VRNA - Earnings call 3 2023 | Verona Pharma plc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to Verona Pharma's Third Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Earlier this morning, Verona Pharma issued a press release announcing its financial results for the three months ended September 30, 2023. A copy can be found in the Investor Relations tab on the corporate website, www.veronapharma.com.

Before we begin, I'd like to remind you that during today's call, statements about the company's future expectations, plans and prospects are forward-looking statements. based current are statements forward-looking on expectations. management's These or nor involve other from known statements results, factors are forward-looking unknown our and promises neither performance actual implied our and These expectations and expressed materially by guarantees risks, may cause to or achievements be that the different important statements. uncertainties date call. conference such statements management's represent this forward-looking estimates of Any as of the

obligation future, to to forward-looking company so, statements update at it may disclaims in point change. the subsequent any While if such the do views even events elect some its to cause

being As and the a reminder, Chief Executive this call I'd Zaccardelli, to David remain is days. for turn now Officer. Dr. like recorded XX Please available ahead. to over call will go

David Zaccardelli

everyone, Mark today's today Commercial. President Dr. welcome, me and Medical Officer; Financial Vice to Hahn, Chief Rickard, Martin, With are our Kathy Chief of Chris Officer; call. Thank you, Senior our our and

agency nonsteroidal believe treatment COPD. to continued in and anti-inflammatory The than potential available June paradigm the COPD for XXXX, as to ensifentrine PDUFA continuing bronchodilator of to is more has the review. mechanism change for the during the quarter expected target We new treatment years. third the is be FDA for the our accepted assigned application activity of action with of Dr. goal review toward treatment FDA our XX, If of to novel treatment in key discuss first with to hosted approved, leader, XX planning maintenance committee in-person date and opinion ensifentrine their of hold We potential our launch not of In the Jamie for an currently U.S. meeting an advisory forward overview the Rutland. look a Recently, and an meeting New senior company's team patients. preparations for approval seeking the novel to The COPD. COPD drug a providing application. management commercial with August, progress ensifentrine ensifentrine we York investor the our provide our that constant patients of work for

of COPD access, meeting, planned ensifentrine, current for treatment detailed for preparations needs, market, the including the we reimbursement of unmet review field a During strategies and of launch shared launch distribution, deployment. plans overview the

For are physician confident those September, hires meeting commercial of very to we it, with Overall, XX-week severe we our team exacerbation COPD will available and we we exacerbation. have In with a With on risk already many in relationships may in who ensifentrine we to built pending quickly and next across data place fronts. key approval are which missed a of moderate in the payer U.S. capitalize our being be of the ensifentrine, this, replay demonstrated analyses of the the and website. both additional June. is launch well believe decrease on the resulted ERS, substantial positioned able ensifentrine presented rate treatment ENHANCE-X at on launch and strong

COPD, to treatment analyses the the of exacerbations the and compared emergency analyses demonstrated resource well ENHANCE-X from exacerbation hospitalizations the ENHANCE-X visits related department study with in rate office annual regardless health tolerated treatment. from and highlighted in was meeting. at recent The groups. the medication it data resulted placebo addition, risk history, substantial of and CHEST ensifentrine and patient October, fewer including pooled reductions ensifentrine care across In utilization impact that COPD treatment additional presented of In physicians' we on visits, with

use. life risk in in COPD. COPD's the Also as Additionally, to symptoms, as rescue The on unspoken fully regardless in at encourages understand severe on subgroup campaign to in the daily daily COPD well practice. engage endpoints CHEST, reductions has treatment reductions impact HCPs analysis function, conversations we data launched campaign impact and patients' improvements and deeper rate therapy the patient of highlights each of titled with ensifentrine lung exacerbations awareness life their medication disease demonstrated resulted of in background quality and in

global development our trial continued to partnering Turning Nuance ensifentrine strategy. in III COPD the of partner Greater in treatment evaluating our Phase their Pharma, has China, for maintenance China.

novel Greater Nuance as and updates key as addressing global to COPD. the role commercialize exclusive for in treatment a to As progresses. rights reminder, and a look has We forward will need China, play Pharma develop such, ensifentrine a the providing trial for in

programs. a clinical Looking ahead, plan with we starting pipeline, initiate to expanding X are our

developing we the a the dose clinical the second and a fixed-dose nebulized on is in anti-inflammatory only. trial believe there LAMA ensifentrine unmet first start of for provide PDE an formulation therapy. and if COPD and safety a of the and dual are nebulizer. Based LAMA for Phase in mechanism with need an half fixed-dose that are of also nonsteroidal Fixed-dose combination used through is the DPI and treatment market commonly of submit of therapies combination ensifentrine FDA fixed ensifentrine of assessing to nebulized II due the feasible glycopyrrolate the formulation investigational bronchodilation of a a formulation plan developed, Historically, a with therapies delivered efficacy via a application has treatment a and COPD. COPD effects glycopyrrolate, XXXX. to patients cleared, pMDI We With in inhibition. research, a with We fixed-dose maintenance combination combination combination drug will

condition no of of lung and and non-cystic clearance, mucociliary is wide, of patients, that ensifentrine airways abnormally PDEX bronchiectasis. exacerbation be where improvement the Additionally, the reduction lung are profile condition second effective burden, with surgery the therapies The plan approved cycle is steroid approved, clinical commence mechanism based that and treat fibrosis there become to in supports FDA. specifically to data the NDA a non-CF patients bronchiectasis by believe damage. This for to including the of a we our Phase treatment XXX,XXX use enhanced cause to patients assess patients. we ensifentrine in could subject If and Physicians safety currently inflammation to lung bronchiectasis. and tissue for trial the affects the in half supporting non-CF clearance severe bronchodilators, exacerbation antibiotic, leading of and of on approximately in clinical PDEX action the efficacy XXXX, a in ensifentrine an COPD II chronic nebulized in infection, function U.S.,

in program call areas, Mark quarter. with are the I to for new regulatory, our commercial and review the We preparation progress over pleased third all financial now development. will turn results our constant including to

Mark Hahn

everyone. million in believe XXXX $XXX.X cash be commercial balance in cash you, ended morning, the and Thank from equivalents. sheet funding anticipated We we good and of We to on pending approval. launch available Dave, loan have third strong under currently the ensifentrine the and our with the XXXX, expected expect regulatory remains U.K. tax receipts hand, including Oxford runway of quarter at with sufficient the of facility, end credit program the the planned least to through U.S. cash

associated and $X.XX a compared share program quarter $X.XX costs due per XX, the was III trial $XX.X XXXX. third net and period as the build-out back quarter of for quarter $X.X the the quarter the potential other of conduct Research complete, all to program due trial people-related a million of loss million The development XXXX. expenses turn were third the were Phase a tax the ordinary $X.X administrative per in payer quarter XXXX. third ENHANCE in incurred primarily under or preparation loss disease ADS to were decrease primarily or decrease increase advancing a ended ended $X enhanced also reconciliation ADS XX, as $X.X XXXX, tax of ordinary the was Q&A. related analysis increase I'll for the work to ended million September of share million and conduct. as include were clinical clinical per of to for increase the Selling, in compared cost operator XXXX, network Phase the $X.X for for an decrease now the This quarter over the credits XXXX, infrastructure in a quarter commercial an and million costs $X.X as of the $X.XX a reported September for education of to primarily $XX.X distribution to for study study the well period people-related of and and as well XXXX, per costs call $XX.X same million The increase same even to $X.XX in For final September after compared commercial information for for This $X.X million costs III with technology development XX, to the in launch. ongoing supplier. same XXXX. million period to impact related This general million in was for significant by represents of was million costs XXXX $X.X loss after related the of costs. offset whereas of net million to financial partially the loss compared received in costs

Operator

Tsai the begin Jefferies. now Instructions] [Operator Our first will comes from question We and with Andrew question answer session.

Andrew Tsai

the all as well. updates Appreciate

really at would just the only agency kind view? accepting going let's your discussions approved. you filing. be is to And the And How asked secondly, is say night, in up to questions risks the about since the relates it can as question keeps PDUFA, have you first What the you here FDA as are exactly what extent guys So NDA? of the what then ensifentrine share.

it low-hanging additional patients Daliresp. be triple launch could be initial As we that specifically initial fruit to taking could think about who think cadence, therapy an after are your realistic an

displace fruit that we immediately low-hanging expect launch? immediately So upon the could can Daliresp be specifically, to ensifentrine

David Zaccardelli

clarifications. the the mid-cycle. questions. this especially in of for the you'd there, launch. and FDA asked is early turn questions, very With on expect, thoughts Great. review for experience, as say the my And to in prior it typical data, I And Andrew, his during course, typical first I'll one questions, different then regard would I over say FDA even Chris Thanks, review normal relatively maybe at to it's would stage, start the and process, on to what for the the

strong CMC, total at So PDUFA again, keeps us is I I across we to we of extremely nonclinical, very ensifentrine, that the clinical view. think risk have an we it's going well risk, submitted our benefit believe, night compelling. With from we and up and to regard feel package think what

comfortable think So at this where time, the FDA review in we're we're process. at I

turn about I'll and that, with So over talk to it Chris the launch.

Christopher Martin

and Andrew, appreciate question. the I Dave, Thanks,

launch that As of a who and physician think the kind prescribe that ensifentrine may is cadence about to. first we patient,

just X.X know today COPD everybody treated We these today. important medications. ground it's a kind I in with think there's patients patients to of with happening what's million maintenance

either start them, try symptomatic. has a they're of help also half add new triple And agent a likely in when a a if the are are single, very risk to to We physicians these or in that patients symptoms, therapies remaining better today know future. hopefully feel and prevent exacerbations the at least dual, to patient of persistent

our what try and on. defending fruit So really, million, think the is about of we as that groups see X.X or hear patients are very if that quickly patients we low-hanging X that in research would there physicians market they

it's The first LABA rate. ensifentrine these the group data, of being they ICS that about to Dave as very at our think they high And a on doing if look or that is the to LABA single a at when potential add are what think or the patients drug and of look they they product. described, data at approved. LAMA And patients

treatment that meter. The patients second about for these are dual additional physicians looking of which And symptom are Daliresp and patients, and on the patients is XX% be that in could ensifentrine of these time help. in patients, in even on group therapy today, of the XX% add the to triple relief potentially arm

X could that about I important patient still here on for in thing that is an too. to in to mechanism Daliresp think talking mind group about physicians be potentially to -- PDEX, keep are there, a that today I'm that add option XX,XXX the there's patients XX,XXX

very in added the that on they doing lives and so in are mechanisms treatment those normal looking remain daily populations, LABA/ICS X to that could easily. either strongly be So on remain can I having by them dual those actively patients single triple to the layer patients be things their patients these patient think are the and on the do new all or we And get that issues patient's driven lives. some for they and that to to of there their daily very of fact physicians symptomatic. that going able They to top want back path, believe distinct it's are bronchodilator ensifentrine

Operator

comes question Rahimi Piper with Sandler. from Next Yasmeen

Yasmeen Rahimi

Would dig some what what II like off. for color into about. formulation a look What these you spoke a the to so said study at little duration have studies us If it also the would then you're for I for soon the a same you you where the and like and love that that updates. completed? much design in And you the X the are this -- fixed more all beyond junction? et Thank you cetera, could you've size, in the Phase second study kick the design would give bit could and be -- would condo? what process how goes planning to new just guess,

love indication cadence And sort be beyond to size, of steps? next maybe for the really associated of costs I bit helpful would would think hear more granular little around with of a them? clients initial us. Just a the So that the lot what's

David Zaccardelli

me and the bronchiectasis. let just both the for as So for combo the I'll fixed as co-formulating formulation turn fixed about ensifentrine with are design formulation. development Within then to talk product Kathy it and nebulized talk trial development, we combo to briefly the where concepts formulation, both and glycopyrrolate over well we're formulation typical advancing about

accelerated longer-term a There's and there's to we on generated Of have acceptable normal formulation. that course, gets commercially that can chemistry data also acute us months, convince X look that typically we under at. and a X at stability conditions

So that aspects stability when point. as up, you're work looking can't sped especially at time we is Certain speak. be X-month ongoing

combo And We the provided initiate somewhere actually studies 'XX. that on why of XXXX. dose expect both second for to the in quarter informed the be in more be we fully bronchiectasis looking co-formulation guidance fixed that's of the we'll the first and half to

design. that, -- over I'll Kathy give it the with for her So turn to thoughts on

Kathleen Rickard

Sure.

talk the So combination. fixes first about let's

to of stages what a early of general the so part like what in we're or to studies that. know how need a do like. II program, in certainly, So look will development initial in Phase would of for We do type we

maybe about XX some up are so. be establish establish ensifentrine more and to initial anywhere that our that a to shorter goals dose be will II and first our also to did So to for to studies we we efficacy likely safety similar probably But Phase with designs or design up need ranging. begin to weeks

safety would is would that that goal of be So at the studies the efficacy look to we do dose-ranging. for and II initial and Phase

study, endpoints longer If safety. the Phase be to of little These of in exacerbations. you II, for be study type We disease, design. efficacy may slightly difference would to and non-CF relate at to different non-CF the slot access establish the a need look second the need because bronchiectasis, certainly some primary studies the again, for

are to of designs further in developing ideas these definite our program. may that we and keep a starting again, mind they make early of So into the about the more we're get But up designs, be as development we design. X-month to in along type phase

Operator

with question next Securities. comes Wedbush Our from Argyrides Andreas

Andreas Argyrides

here. couple A

not there Is for a the threshold Ad So you what a and on expectations Comm, there point history necessarily would And likely bad an whim. of of like held? an can efficacy don't and label ensifentrine, it an a remind if and its Comm, look the you approval FDA while Ad changing is a thing? is be safety from to then standpoint? has mind expect us would be which Ad Comm curious definitely And at

David Zaccardelli

again, to the to We'd, conversations. time indication. an label support COPD, of data in the of clinical expect with that appropriate. of and treatment remind Great. in have approvals, just data provided believe that a for maintenance and data and to to as the everybody we regard supports indication FDA which expect rest indication results and the provided some Clearly, broad we be With fairly away the specific label needs is course, ensifentrine, to recent consistent review, the we're the from the quite of the section labeling continue clinical

so think in that And we'll see I'm comes out. I XXXX. how sure

but otherwise, Yes, not think Comm. have Ad indication an -- fairly is to the they've yes, And plan to broad. Ad we guided do that So regard you're they With Comm. correct.

timing how the want as that FDA into as XXXX, review. and we on mid-cycle I by, one and gets can the for especially expect shorter to decide example, they think that address even during shorter. We get time don't passes after review,

So there's it's And comment hands. Comm. FDA's the on Ad it. further course, certain practicalities I But wouldn't of the about in any nonetheless,

Andreas Argyrides

new us. maybe incident. thoughts from X on And how value strategic unlocks last follow-up and just regard With company some the this indications, the just potentially one to potential for

David Zaccardelli

I by sure. mean Well, -- can of a ensifentrine think Yes. broadly in itself in what combination do as speaks the loudly we believe to treatment I therapy. it either COPD, or

We the as combining have excellent an a advantageous well. quite ENHANCE from ensifentrine is cleaned LAMA with trials data that

the And loudly course, which demonstrated. has and mechanism application. PDEX, power that reviewed in it so think the and to ensifentrine, its the of bronchiectasis we've I today non-CF pharmacology, as speaks then, broader been than because of underlying of And PDEX

other think diseases So in applicable COPD, we like bronchiectasis. highly clearly, it's in

the I respiratory quite applied beginning we've the pharmacology widely can various think potential ensifentrine's as can be diseases, that ultimately, full to really partner of see underlying which stated any from ensifentrine.

Operator

Joon from comes with Truist question next Securities. Lee The

Unknown Analyst

expect XXX-person to hiring Joon. if front? in updates you in wondering force. what European for one partner? first also guide looking around preparation could SG&A for any and that on just talk you are for is, could a sales ramp in Asman question can And is This on launch the you My about for the then And

David Zaccardelli

for regard to be with that look talk it Mark to partnering to think reps. But the I turn to partnering SG&A and same, we then to outside the China over partner to our about I'll with done partner we've U.S., in the that Pharma. continues Greater Chris, Nuance is speak general, strategy, European or, as in the Great. it and much

strategy not the changed. has So

a elements in of course, you'd ideally around clinical think the otherwise, partner, that I expect. in European in commercial respiratory besides, or as expertise space, regulatory, and

and in as product, or cycle I full for opportunities DPI I that the think ensifentrine advantageous us And potentially quite partners we're have We world API. and/or which would but of different looking a substance for also manufacture or are IP, that second expertise course, device in PMD management looking the with to ensifentrine supply manufacturing indications point. for ability to this think be could a having, look in source drug cost as well as potentially development, drug also mind we with serve other device lower that Keep in well specifically markets. a source life

And looking our capability with is for partnering so strategy. somebody feature that another of manufacturing

to over So for that, turn it with Mark ramp a SG&A. I'll on

Mark Hahn

Sure.

if expense would see of is talk ramping QX, And total get then approval to ramps what this bring and $XX-ish you of Through you of sales R&D. total $XX through think next that $XX So the million June, last again SG&A reps be couple in QX, year, as I at that, should that in think range that to year, see was that our our quarters. the years, the about. will And once the Chris quarterly that ago, the QX, assuming expense expect we the million both at will basis. on million. on SG&A and that for look includes a a That you we million think several should $X-ish it end you'll it's SG&A I continue over been QX year next has it ramp I

Christopher Martin

Thanks, Mark, that. on

which we force organization. first potentially Joon, As about typically, about look field and XXX, sales like how And then a next west. we we the is the under area reps this quickly when candidates X people, east directors how a regional on. And in cover sales about on them of And would we actively an months have hire directors directors, that, a until team past at looking around we cover into that think you're pool X be to is the you type before going offers individuals structure we're expect and to an looks level that for think these the And around is of have to and of of at our RSDs, X to which we maybe able for executive to executive We've or as kind those brought are at employees active PDUFA. managers. where organization. the hold PDUFA. approved and people those X PDUFA to convert PDUFA directly rep the hire contingent our are a create with plan hire the drug reps We've that hired would date those done the

have would plan PDUFA them those have ensifentrine and to ready to reps approved. be come So go trained and on it's after then if our right sell

the aspect that is and a I support field doctors believe think interact ways managers. reps, that here we reimbursement reimbursement the virtually field-based ensifentrine not important with with but also other covering proper also includes we pathway only force field can

product think the as of that and large after can in and we would to And how sure the need. number again, then the patients the PDUFA. about think -- most organization, in but cover utility that we see the a to the physicians support people I the get of that they right to So of PDUFA way they the totality can want coming that around commercial are that patients those also be -- representatives product make all you

Operator

question Next with Shrader comes Tom from BTIG.

Thomas Shrader

questions. combination all I've

Kathy, to eager that bronchiectasis. repeat? you something work follow-up ensifentrine. is was LAMA would Or can you try So that hold It mind? that quite to ever you class? it for striking is that data working up the there's the really some for on data you're LAMA's Maybe then if made mechanisms together? really old out? derisking the your very is I a specific And be faster. play that used, not for in The And does see it molecules how have And

David Zaccardelli

how Yes, talk her potentially and to about and turn to work it Tom. Thanks, general glycopyrrolate, in glycopyrrolate then I'll Kathy together. over ensifentrine Great.

Kathleen Rickard

Yes.

So similar. use a in other Works glycopyrrolate is for like very They've time. been LAMAs. long

from we and that know they perspective, lot them a fairly work all about similar. So

I So FSC or any that expect from to studies look at surprises from whatever that have in we don't perspective. their

that were acting expect not but for peak studies, done have perspective. that faster, would as that that far when shortening go we in in do but combine beta that to LAMAs, was I we together, As see agonist just I there older away. use them wouldn't -- also that it's shows shorter I'm the the some a together do that would Again, of the question data I response expect those efficacy. still of get another X when you to you type combination forgetting? don't from time

Thomas Shrader

I asked it yet. haven't

Just you historically and the anti-inflammatory properties as or mostly tried Are this bronchodilators focused failed? an to on effective been bronchiectasis, have betting show on drug?

Kathleen Rickard

Bronchodilators per have not se. failed

of COPD, see some As things and similar infections, airways example, that was they we and bronchiectasis. destruction the that non-CF have drugs had in widening to mentioned, airways increased for mucus. are approved Bronchiectasis there are similar the for they no have

they we ensifentrine in see So COPD. we many bronchiectasis, things that see the of effects and from --

have then you to looking and lead there like you're if those airways the for the to the exacerbations. you're but infected because infections So getting better. doesn't actually It where would rid and when gets bronchodilate you stuff you it the clear necessarily all that's of sitting for sitting may what's mucus the with mucus somebody in increasing, in bronchodilation see airway, out underlying help example, asthma work causing all looking actually

everything to use we because them? we do don't use them. We use. we have So anything we use else Yes, have

that's bronchodilators, whatever to can So use have going for bronchiectasis. have treat we use you, available to we because steroids use to you we're or what

I the think the effect mucus that we with may on of and out and to and perspective, help bronchiectasis. clearance will its clear ensifentrine prevent airways both increase help mucociliary decrease exacerbations with think we from patients ability also see non-steroidal anti-inflammatory

Operator

[Operator from Wainwright. Patel question Instructions] with Our comes Dipesh H.C. next

Dipesh Patel

schedule the least one Boobalan, market others. that for twice-a-day last Dipesh, attribute see slides among covering HCP-focused preferred is In Wainwright. presented research the that of X dosing month, This ensifentrine's you we H.C. was

Thinking to was how you market potentially regimen impact score long that do the So ensifentrine's the term, not twice-a-day bad. adoption? expect

David Zaccardelli

Great. Chris, to do it? speak you to want

Christopher Martin

and Yes. Dipesh. Thanks, Dave, the appreciate question, I

Attribute I on rated of referring the the you're slide drugs. ensifentrine that. to how think attributes to physicians and

profile think ground impressive really how was to ensifentrine. response the physicians the important of it's I from on just on ourselves

plays it's you that attribute for score, score in need the that above that interactions marketplace.As but As symptoms. in discussed extraordinarily median. well that's was every KOL from think high the unmet qualitative within still the what most important, we've is on still heard lowest mindset. mentioned, I And to and are important, physician's listed least persistent XX% But the exists patients based we having these ensifentrine earlier, a the of

over We talk BID the to struggle their lose that tend potentially hear they ensifentrine can them So have. but what many things struggle, we interesting looking in Kathy patient specifically the wake from the physicians patients many talk when time. on effect drugs effect about of or their about is doctors are for drugs have morning that and single dosing, the this, once-a-day could potential that's patients to because is to that up one an have lives

they mind, their once-a-day dosing patient wake the a to in So the for maybe sometimes very get that would dose place than a them BID is with up allows in product. because have type beneficial better that they evening single

it, high adopting within ensifentrine need believe remarkably they'll has. launch. hindrance all. BID the we of profile, a a unmet HCPs that you the that So dose first that adoption that And that that's at see on and be a don't basically that look the year physicians is second when at part ensifentrine the at differentiated profile the we speaks of XX% overall says again, And can believe the to rate. and how overall look of which adoption And slide,

Dipesh Patel

have couple I questions. Great. of a more

noted may touched testing prior in you plus the of on the on on discuss of expecting had earlier going anticipate on, half in this that a begin have combinability the clinical You you single think confirm ensifentrine as nebulizer formulation. you challenges just And LAMA to trial be that? second you you're some solving work can 'XX of I questions, the to to but

David Zaccardelli

Yes.

to the be for general the new you see support I the the would plan That's the other co-formulated nothing data to development to need work both we done that cadence the believe because With the glycopyrrolate, ongoing. that we ensifentrine nothing formulation. where is want having drug for of and getting support formulation is and Our that know that. than delivered it's development. in to to through durability sure it which we think We formulation make takes the work that development And when need regard to be. getting forward, can we're want some -- dose activities, data time but we challenges, the work,

a ensifentrine, lot of all aspects the course, with chemistry, there's which, need formulation, dose a of combination. that So we in generation, work, of we've with the the done do size technical deliver, previously particle the to

in ongoing. why at So trial will that us second work a half puts of clinical XXXX. that's the it in looking And be

Dipesh Patel

what should we expenses Got to? will think R&D the R&D moving remaining it. And final about question. expense How relate forward? Specifically,

David Zaccardelli

Mark. ahead, Go

Mark Hahn

question. the for Thanks Yes.

to not be should we're running because in clinical think any trials. very I R&D the near term, fairly expenses So expect limited you

they should program. that They're Phase used our are get smaller. not into the seeing programs much next the of about to back that year, up ensifentrine marginally. These II you we talking As III scope half in same during we're Phase go

be expense So had the levels more Verona time XXXX in the frame. like will back

until low R&D get single-digit, expense mid-single-digit foreseeable think future to quarterly for III to a I Phase we program. the

Operator

Dr. question-and-answer conference our David Zaccardelli session. like to to back closing I the concludes This turn would any for over remarks.

David Zaccardelli

and appreciate we the conferences. everybody, your a look We today's for great day. call. attending support, updating Have forward you, you Thank in future to at Great.

Operator

Thank now has for conference presentation. today's you concluded. The attending

You may disconnect. all now

Verona Pharma (VRNA) 2 Nov 232023 Q3 Earnings call transcript